WO2007100614A3 - FORMULATION NON CRISTALLINE STABLE COMPRENANT UN INHIBITEUR DE LA HMG-CoA RÉDUCTASE - Google Patents

FORMULATION NON CRISTALLINE STABLE COMPRENANT UN INHIBITEUR DE LA HMG-CoA RÉDUCTASE Download PDF

Info

Publication number
WO2007100614A3
WO2007100614A3 PCT/US2007/004629 US2007004629W WO2007100614A3 WO 2007100614 A3 WO2007100614 A3 WO 2007100614A3 US 2007004629 W US2007004629 W US 2007004629W WO 2007100614 A3 WO2007100614 A3 WO 2007100614A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
hmg
coa reductase
reductase inhibitor
stable non
Prior art date
Application number
PCT/US2007/004629
Other languages
English (en)
Other versions
WO2007100614A2 (fr
Inventor
Nageshwara Palepu
Andreas Kordikowski
Jiang Zhang
Sarma Duddu
David Lechuga
Mei Chang Kuo
Original Assignee
Scidose Llc
Nageshwara Palepu
Andreas Kordikowski
Jiang Zhang
Sarma Duddu
David Lechuga
Mei Chang Kuo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scidose Llc, Nageshwara Palepu, Andreas Kordikowski, Jiang Zhang, Sarma Duddu, David Lechuga, Mei Chang Kuo filed Critical Scidose Llc
Publication of WO2007100614A2 publication Critical patent/WO2007100614A2/fr
Publication of WO2007100614A3 publication Critical patent/WO2007100614A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Abstract

Un ou plusieurs modes de réalisation de la présente invention concernent une formulation comprenant un inhibiteur de la HMG-CoA réductase, des co-formulations d'inhibiteurs de la HMG-CoA réductase avec des excipients, des procédés de préparation de ces formulations, des compositions pharmaceutiques comprenant les formulations, et leur utilisation dans un traitement médical. L'invention concerne également des formulations pharmaceutiques à usage oral stables comprenant des inhibiteurs de la HMG-CoA réductase tels que l'atorvastatine, des procédés correspondants pour les préparer, ainsi que l'utilisation (administration) des formulations et co-formulations pharmaceutiques à usage oral stables. Ces formulations possèdent des caractéristiques de solubilité ou de dissolution voulues, en particulier améliorées ou renforcées, ce qui se traduit par une biodisponibilité et/ou une pharmacocinétique voulues, en particulier améliorées ou renforcées.
PCT/US2007/004629 2006-02-24 2007-02-20 FORMULATION NON CRISTALLINE STABLE COMPRENANT UN INHIBITEUR DE LA HMG-CoA RÉDUCTASE WO2007100614A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77652506P 2006-02-24 2006-02-24
US60/776,525 2006-02-24

Publications (2)

Publication Number Publication Date
WO2007100614A2 WO2007100614A2 (fr) 2007-09-07
WO2007100614A3 true WO2007100614A3 (fr) 2008-10-02

Family

ID=38459549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/004629 WO2007100614A2 (fr) 2006-02-24 2007-02-20 FORMULATION NON CRISTALLINE STABLE COMPRENANT UN INHIBITEUR DE LA HMG-CoA RÉDUCTASE

Country Status (1)

Country Link
WO (1) WO2007100614A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA023338B1 (ru) * 2007-10-17 2016-05-31 Тодд Ф. Овокайтис Способ модификации твердого состояния соединения и соаморфные композиции, полученные этим способом
CZ300964B6 (cs) * 2008-05-19 2009-09-23 Výzkumný ústav pivovarský a sladarský, a.s. Zpusob termogravimetrického stanovení vlhkosti pivovarských surovin
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
WO2015187974A1 (fr) 2014-06-06 2015-12-10 Ovokaitys Todd Frank Procédés et compositions pour augmenter l'activité biologique de nutriments
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
BR112017004127B1 (pt) * 2014-08-28 2023-04-11 Lipocine Inc Composição farmacêutica oral
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
GB2600464A (en) * 2020-10-30 2022-05-04 Cubic Pharmaceuticals Ltd Process of preparing active pharmaceutical ingredient salts

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050079138A1 (en) * 2002-12-19 2005-04-14 Chickering Donald E. Methods for making pharmaceutical formulations comprising microparticles with improved dispersibility, suspendability or wettability

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050079138A1 (en) * 2002-12-19 2005-04-14 Chickering Donald E. Methods for making pharmaceutical formulations comprising microparticles with improved dispersibility, suspendability or wettability
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin

Also Published As

Publication number Publication date
WO2007100614A2 (fr) 2007-09-07

Similar Documents

Publication Publication Date Title
WO2007100614A3 (fr) FORMULATION NON CRISTALLINE STABLE COMPRENANT UN INHIBITEUR DE LA HMG-CoA RÉDUCTASE
CA2795804C (fr) Compositions pharmaceutiques de l'acide 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yle) cyclopropanecarboxamido)-3-methylpyridin-2-yle)benzoique et leur administration
WO2006082523A3 (fr) Compositions pharmaceutiques de metformine
EP2842559A3 (fr) Composes, compositions et methodes de traitement d'infections virales et autres troubles medicaux
WO2011014850A3 (fr) Formulations à usage topique à base d'un eutectique
WO2008002245A3 (fr) Nouveaux composés 385
WO2009024611A3 (fr) 4-benzylaminoquinoléines, compositions pharmaceutiques les contenant, et leur utilisation en thérapie
WO2008038003A3 (fr) Compositions pharmaceutiques
WO2007014124A3 (fr) Formes posologiques et preparations a charge medicamenteuse elevee
MX2009000482A (es) Compuestos terapeuticos.
MY145581A (en) Combination of ferroquine and an artemisinin derivative for the treatment of malaria
MX2011005643A (es) Formas de dosificacion oral de bendamustina.
WO2008006795A3 (fr) Composés d'indole
WO2011142621A3 (fr) Formulation pharmaceutique sous la forme de comprimés bicouches comprenant un inhibiteur de hmg-coa réductase et d'irbésartan
WO2009032843A3 (fr) Aminoalcools substitués
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
WO2008020314A3 (fr) Formulations de dosage stabilisantes à base de statine
WO2008013823A3 (fr) Co-cristaux de (2r-trans)-6-chloro-5-[[4-[(4-fluorophényl)méthyl]-2,5-diméthyl-1-pipérazinyl]carbonyl]-n,n,1-triméthyl-alpha-oxo-1h-indole-3-acétamide
PL1806130T3 (pl) Kompozycja farmaceutyczna w postaci stałej zawierająca irbesartan
WO2008004100A3 (fr) Composés thérapeutiques
WO2005120518A3 (fr) Utilisation d'analogues d'atp pour le traitement des maladies cardio-vasculaires
WO2008039894A3 (fr) Compositions pharmaceutiques d'atorvastatine
WO2007110765A3 (fr) Procedes de preparation d'octreotide
WO2006138431A3 (fr) Procedes et preparations pharmaceutiques pour l'accroissement de la biodisponibilite
TW200716114A (en) Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07751395

Country of ref document: EP

Kind code of ref document: A2